We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
Read MoreHide Full Article
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.
Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
Harmony Biosciences (HRMY - Free Report) is a stock many investors are watching right now. HRMY is currently sporting a Zacks Rank #2 (Buy) and an A for Value.
We should also highlight that HRMY has a P/B ratio of 2.42. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. HRMY's current P/B looks attractive when compared to its industry's average P/B of 3.82. HRMY's P/B has been as high as 4.20 and as low as 2.23, with a median of 2.87, over the past year.
Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a preferred metric because revenue can't really be manipulated, so sales are often a truer performance indicator. HRMY has a P/S ratio of 2.42. This compares to its industry's average P/S of 6.12.
Finally, investors should note that HRMY has a P/CF ratio of 9.34. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. HRMY's current P/CF looks attractive when compared to its industry's average P/CF of 11.24. Within the past 12 months, HRMY's P/CF has been as high as 16.61 and as low as 9.07, with a median of 11.73.
These are just a handful of the figures considered in Harmony Biosciences's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that HRMY is an impressive value stock right now.
View the Zacks #1 Rank List
Image: Bigstock
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.
Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
Harmony Biosciences (HRMY - Free Report) is a stock many investors are watching right now. HRMY is currently sporting a Zacks Rank #2 (Buy) and an A for Value.
We should also highlight that HRMY has a P/B ratio of 2.42. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. HRMY's current P/B looks attractive when compared to its industry's average P/B of 3.82. HRMY's P/B has been as high as 4.20 and as low as 2.23, with a median of 2.87, over the past year.
Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a preferred metric because revenue can't really be manipulated, so sales are often a truer performance indicator. HRMY has a P/S ratio of 2.42. This compares to its industry's average P/S of 6.12.
Finally, investors should note that HRMY has a P/CF ratio of 9.34. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. HRMY's current P/CF looks attractive when compared to its industry's average P/CF of 11.24. Within the past 12 months, HRMY's P/CF has been as high as 16.61 and as low as 9.07, with a median of 11.73.
These are just a handful of the figures considered in Harmony Biosciences's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that HRMY is an impressive value stock right now.